Moreover, Gong et al. found that LOXL2 enhanced resistance to chemotherapy drugs by activating the ITGA5/FAK/PI3K/ROCK1 signaling pathway in liver cancer, whereas silencing LOXL2 restored the efficacy of the drug [18]. This evidence concerns the gene ITGA5 and liver cancer.